Tcheng JE - Search Results

1

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Gurm HS, et al. Among authors: tcheng je. Heart. 2003 Oct;89(10):1200-4. doi: 10.1136/heart.89.10.1200. Heart. 2003. PMID: 12975419 Free PMC article.

2

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.

Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM. Topol EJ, et al. Among authors: tcheng je. Am J Med. 2002 Jul;113(1):1-6. doi: 10.1016/s0002-9343(02)01145-2. Am J Med. 2002. PMID: 12106616 Clinical Trial.

3

Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials.

Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Ellis K, et al. Among authors: tcheng je. J Interv Cardiol. 2003 Aug;16(4):299-305. doi: 10.1034/j.1600-6143.2003.08062.x. J Interv Cardiol. 2003. PMID: 14562669 Clinical Trial.

4

Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.

Gurm HS, Lincoff AM, Kleiman NS, Kereiakes DJ, Tcheng JE, Aronow HD, Askari AT, Brennan DM, Topol EJ. Gurm HS, et al. Among authors: tcheng je. Am J Cardiol. 2004 Jul 1;94(1):30-4. doi: 10.1016/j.amjcard.2004.03.025. Am J Cardiol. 2004. PMID: 15219504

5

Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.

Rajagopal V, Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Rajagopal V, et al. Among authors: tcheng je. Am J Cardiol. 2004 Jul 15;94(2):190-2. doi: 10.1016/j.amjcard.2004.03.060. Am J Cardiol. 2004. PMID: 15246898

6

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.

Exaire JE, Tcheng JE, Kereiakes DJ, Kleiman NS, Applegate RJ, Moliterno DJ; ELECT Investigators. Exaire JE, et al. Among authors: tcheng je. Catheter Cardiovasc Interv. 2005 Mar;64(3):369-72. doi: 10.1002/ccd.20257. Catheter Cardiovasc Interv. 2005. PMID: 15736260 Clinical Trial.

7

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Topol EJ, et al. Among authors: tcheng je. JAMA. 1997 Aug 13;278(6):479-84. doi: 10.1001/jama.278.6.479. JAMA. 1997. PMID: 9256222 Clinical Trial.

8

Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.

Bhatt DL, Lincoff AM, Kereiakes DJ, Tcheng JE, Simoons ML, van der Wieken LR, Godfrey N, Califf RM, Topol EJ. Bhatt DL, et al. Among authors: tcheng je. Am J Cardiol. 1998 Nov 1;82(9):1105-6, A6. doi: 10.1016/s0002-9149(98)00565-7. Am J Cardiol. 1998. PMID: 9817488

9

Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.

Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ. Ellis SG, et al. Among authors: tcheng je. J Am Coll Cardiol. 1998 Nov 15;32(6):1619-23. doi: 10.1016/s0735-1097(98)00403-3. J Am Coll Cardiol. 1998. PMID: 9822087 Free article. Clinical Trial.

10

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Lincoff AM, et al. Among authors: tcheng je. Circulation. 1999 Apr 20;99(15):1951-8. doi: 10.1161/01.cir.99.15.1951. Circulation. 1999. PMID: 10208997 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters